

Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)

Resource impact template	Resource impact for selected population using standard NICE assumptions			Resource impact for selected population using standard NICE assumptions		
	Per 100,000 population			Cumbria		
	Unit cost (£) / proportion	Units	Total cost (£)	Unit cost (£) / proportion	Units	Total cost (£)
Total population selected		100,000			504,138	
People with heart failure	0.76%	763		0.76%	3,845	
People with heart failure with reduced left ventricular ejection fraction	72.00%	549		72.00%	2,768	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms	71.10%	390		71.10%	1,968	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms, with a left ventricular ejection fraction of 35% or less	59.50%	232		59.50%	1,171	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms, with a left ventricular ejection fraction of 35% or less and taking an ACE inhibitor/ARB	85.95%	199		85.95%	1,006	
<b>Current practice</b>						
People having an ACE inhibitor	85.00%	169		85.00%	855	
People having an ARB	15.00%	30		15.00%	151	
People having sacubitril valsartan	0.00%	-		0.00%	-	
<b>Annual treatment costs</b>						
ACEi (weighted average)	£31.59	169	£5,339	£31.59	855	£27,009
ARB (Weighted average)	£86.71	30	£2,601	£86.71	151	£13,093
Sacubitril valsartan	£1,193.55	-	£0	£1,193.55	-	£0
<b>Estimated costs of current practice</b>			<b>£7,940</b>			<b>£40,102</b>
<b>Future practice</b>						
People having an ACE inhibitor	34.40%	68		34.40%	346	
People having an ARB	5.60%	11		5.60%	56	
People having sacubitril valsartan	60.00%	119		60.00%	604	
<b>Annual treatment costs</b>						
ACEi (weighted average)	£31.59	68	£2,148	£31.59	346	£10,930
ARB (Weighted average)	£86.71	11	£954	£86.71	56	£4,856
Sacubitril valsartan	£1,193.55	119	£142,032	£1,193.55	604	£720,904
<b>Estimated costs of future practice</b>			<b>£145,134</b>			<b>£736,690</b>
<b>Reduced hospital admissions associated with switching from an ACE inhibitor to sacubitril valsartan</b>						
People switching from an ACE inhibitor to sacubitril valsartan		101			509	
All-cause hospitalisation rate for heart failure associated with sacubitril valsartan	31.81%	32		31.81%	162	
Reduced annual hospital admissions using sacubitril valsartan instead of an ACE inhibitor	-3.71%	-4		-3.71%	-19	
<b>Unit costs</b>						
Heart failure	£2,697.69	-4	-£10,791	£2,697.69	-19	-£51,256
<b>Estimated costs of future practice</b>			<b>-£10,791</b>			<b>-£51,256</b>
<b>Net resource impact</b>			<b>£126,404</b>			<b>£645,332</b>
<b>Potential changes to drug costs (VAT and discounts)</b>						
<b>VAT</b>						
	Total VAT applicable drug costs	Drug cost including discounts and VAT	Adjustment	Total VAT applicable drug costs	Drug cost including discounts and VAT	Adjustment
Current practice	£7,940	7,940	-	£40,102	40,102	-
Future practice	£145,134	145,134	-	736,690	736,690	-
<b>Impact of changes in drug cost</b>			<b>£0</b>			<b>£0</b>
<b>Amended resource impact of guidance</b>			<b>£126,404</b>			<b>£645,332</b>

**Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)**

Resource impact template	Resource impact for selected population using standard NICE assumptions			Resource impact for selected population using standard NICE assumptions		
	Darlington			Durham Dales, Easington and Sedgfield		
	Unit cost (£) / proportion	Units	Total cost (£)	Unit cost (£) / proportion	Units	Total cost (£)
Total population selected		105,396			272,903	
People with heart failure	0.76%	804		0.76%	2,081	
People with heart failure with reduced left ventricular ejection fraction	72.00%	579		72.00%	1,498	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms	71.10%	412		71.10%	1,065	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms, with a left ventricular ejection fraction of 35% or less	59.50%	245		59.50%	634	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms, with a left ventricular ejection fraction of 35% or less and taking an ACE inhibitor/ARB	85.95%	211		85.95%	545	
<b>Current practice</b>						
People having an ACE inhibitor	85.00%	179		85.00%	463	
People having an ARB	15.00%	32		15.00%	82	
People having sacubitril valsartan	0.00%	-		0.00%	-	
<b>Annual treatment costs</b>						
ACEi (weighted average)	£31.59	179	£5,655	£31.59	463	£14,626
ARB (Weighted average)	£86.71	32	£2,775	£86.71	82	£7,110
Sacubitril valsartan	£1,193.55	-	£0	£1,193.55	-	£0
<b>Estimated costs of current practice</b>			<b>£8,429</b>			<b>£21,736</b>
<b>Future practice</b>						
People having an ACE inhibitor	34.40%	73		34.40%	187	
People having an ARB	5.60%	12		5.60%	31	
People having sacubitril valsartan	60.00%	127		60.00%	327	
<b>Annual treatment costs</b>						
ACEi (weighted average)	£31.59	73	£2,306	£31.59	187	£5,907
ARB (Weighted average)	£86.71	12	£1,041	£86.71	31	£2,688
Sacubitril valsartan	£1,193.55	127	£151,581	£1,193.55	327	£390,291
<b>Estimated costs of future practice</b>			<b>£154,927</b>			<b>£398,886</b>
<b>Reduced hospital admissions associated with switching from an ACE inhibitor to sacubitril valsartan</b>						
People switching from an ACE inhibitor to sacubitril valsartan		106			276	
All-cause hospitalisation rate for heart failure associated with sacubitril valsartan	31.81%	34		31.81%	88	
Reduced annual hospital admissions using sacubitril valsartan instead of an ACE inhibitor	-3.71%	-4		-3.71%	-10	
<b>Unit costs</b>						
Heart failure	£2,697.69	-4	-£10,791	£2,697.69	-10	-£26,977
<b>Estimated costs of future practice</b>			<b>-£10,791</b>			<b>-£26,977</b>
<b>Net resource impact</b>			<b>£135,707</b>			<b>£350,173</b>
<b>Potential changes to drug costs (VAT and discounts)</b>						
<b>VAT</b>						
	Total VAT applicable drug costs	Drug cost including discounts and VAT	Adjustment	Total VAT applicable drug costs	Drug cost including discounts and VAT	Adjustment
Current practice	£8,429	8,429	-	£21,736	21,736	-
Future practice	154,927	154,927	-	398,886	398,886	-
<b>Impact of changes in drug cost</b>			<b>£0</b>			<b>£0</b>
<b>Amended resource impact of guidance</b>			<b>£135,707</b>			<b>£350,173</b>

**Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)**

Resource impact template	Resource impact for selected population using standard NICE assumptions			Resource impact for selected population using standard NICE assumptions		
	Gateshead			Hartlepool and Stockton-on-Tees		
	Unit cost (£) / proportion	Units	Total cost (£)	Unit cost (£) / proportion	Units	Total cost (£)
Total population selected		199,998			285,861	
People with heart failure	0.76%	1,525		0.76%	2,180	
People with heart failure with reduced left ventricular ejection fraction	72.00%	1,098		72.00%	1,570	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms	71.10%	781		71.10%	1,116	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms, with a left ventricular ejection fraction of 35% or less	59.50%	465		59.50%	664	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms, with a left ventricular ejection fraction of 35% or less and taking an ACE inhibitor/ARB	85.95%	400		85.95%	571	
<b>Current practice</b>						
People having an ACE inhibitor	85.00%	340		85.00%	485	
People having an ARB	15.00%	60		15.00%	86	
People having sacubitril valsartan	0.00%	-		0.00%	-	
<b>Annual treatment costs</b>						
ACEi (weighted average)	£31.59	340	£10,740	£31.59	485	£15,321
ARB (Weighted average)	£86.71	60	£5,203	£86.71	86	£7,457
Sacubitril valsartan	£1,193.55	-	£0	£1,193.55	-	£0
<b>Estimated costs of current practice</b>			<b>£15,943</b>			<b>£22,778</b>
<b>Future practice</b>						
People having an ACE inhibitor	34.40%	138		34.40%	196	
People having an ARB	5.60%	22		5.60%	32	
People having sacubitril valsartan	60.00%	240		60.00%	343	
<b>Annual treatment costs</b>						
ACEi (weighted average)	£31.59	138	£4,359	£31.59	196	£6,192
ARB (Weighted average)	£86.71	22	£1,908	£86.71	32	£2,775
Sacubitril valsartan	£1,193.55	240	£286,452	£1,193.55	343	£409,388
<b>Estimated costs of future practice</b>			<b>£292,719</b>			<b>£418,354</b>
<b>Reduced hospital admissions associated with switching from an ACE inhibitor to sacubitril valsartan</b>						
People switching from an ACE inhibitor to sacubitril valsartan		202			289	
All-cause hospitalisation rate for heart failure associated with sacubitril valsartan	31.81%	64		31.81%	92	
Reduced annual hospital admissions using sacubitril valsartan instead of an ACE inhibitor	-3.71%	-8		-3.71%	-11	
<b>Unit costs</b>						
Heart failure	£2,697.69	-8	-£21,582	£2,697.69	-11	-£29,675
<b>Estimated costs of future practice</b>			<b>-£21,582</b>			<b>-£29,675</b>
<b>Net resource impact</b>			<b>£255,194</b>			<b>£365,901</b>
<b>Potential changes to drug costs (VAT and discounts)</b>						
<b>VAT</b>						
	Total VAT applicable drug costs	Drug cost including discounts and VAT	Adjustment	Total VAT applicable drug costs	Drug cost including discounts and VAT	Adjustment
Current practice	£15,943	15,943	-	£22,778	22,778	-
Future practice	292,719	292,719	-	418,354	418,354	-
<b>Impact of changes in drug cost</b>			<b>£0</b>			<b>£0</b>
<b>Amended resource impact of guidance</b>			<b>£255,194</b>			<b>£365,901</b>

**Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)**

Resource impact template	Resource impact for selected population using standard NICE assumptions			Resource impact for selected population using standard NICE assumptions		
	Newcastle North and East			Newcastle West		
	Unit cost (£) / proportion	Units	Total cost (£)	Unit cost (£) / proportion	Units	Total cost (£)
Total population selected		143,885			142,936	
People with heart failure	0.76%	1,097		0.76%	1,090	
People with heart failure with reduced left ventricular ejection fraction	72.00%	790		72.00%	785	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms	71.10%	562		71.10%	558	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms, with a left ventricular ejection fraction of 35% or less	59.50%	334		59.50%	332	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms, with a left ventricular ejection fraction of 35% or less and taking an ACE inhibitor/ARB	85.95%	287		85.95%	285	
<b>Current practice</b>						
People having an ACE inhibitor	85.00%	244		85.00%	242	
People having an ARB	15.00%	43		15.00%	43	
People having sacubitril valsartan	0.00%	-		0.00%	-	
<b>Annual treatment costs</b>						
ACEi (weighted average)	£31.59	244	£7,708	£31.59	242	£7,645
ARB (Weighted average)	£86.71	43	£3,729	£86.71	43	£3,729
Sacubitril valsartan	£1,193.55	-	£0	£1,193.55	-	£0
<b>Estimated costs of current practice</b>			<b>£11,436</b>			<b>£11,373</b>
<b>Future practice</b>						
People having an ACE inhibitor	34.40%	99		34.40%	98	
People having an ARB	5.60%	16		5.60%	16	
People having sacubitril valsartan	60.00%	172		60.00%	171	
<b>Annual treatment costs</b>						
ACEi (weighted average)	£31.59	99	£3,127	£31.59	98	£3,096
ARB (Weighted average)	£86.71	16	£1,387	£86.71	16	£1,387
Sacubitril valsartan	£1,193.55	172	£205,291	£1,193.55	171	£204,097
<b>Estimated costs of future practice</b>			<b>£209,805</b>			<b>£208,580</b>
<b>Reduced hospital admissions associated with switching from an ACE inhibitor to sacubitril valsartan</b>						
People switching from an ACE inhibitor to sacubitril valsartan		145			144	
All-cause hospitalisation rate for heart failure associated with sacubitril valsartan	31.81%	46		31.81%	46	
Reduced annual hospital admissions using sacubitril valsartan instead of an ACE inhibitor	-3.71%	-6		-3.71%	-5	
<b>Unit costs</b>						
Heart failure	£2,697.69	-6	-£16,186	£2,697.69	-5	-£13,488
<b>Estimated costs of future practice</b>			<b>-£16,186</b>			<b>-£13,488</b>
<b>Net resource impact</b>			<b>£182,183</b>			<b>£183,719</b>
<b>Potential changes to drug costs (VAT and discounts)</b>						
VAT						
	Total VAT applicable drug costs	Drug cost including discounts and VAT	Adjustment	Total VAT applicable drug costs	Drug cost including discounts and VAT	Adjustment
Current practice	£11,436	11,436	-	£11,373	11,373	-
Future practice	209,805	209,805	-	208,580	208,580	-
<b>Impact of changes in drug cost</b>			<b>£0</b>			<b>£0</b>
<b>Amended resource impact of guidance</b>			<b>£182,183</b>			<b>£183,719</b>

**Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)**

Resource impact template	Resource impact for selected population using standard NICE assumptions			Resource impact for selected population using standard NICE assumptions		
	North Durham			North Tyneside		
	Unit cost (£) / proportion	Units	Total cost (£)	Unit cost (£) / proportion	Units	Total cost (£)
Total population selected		243,054			202,152	
People with heart failure	0.76%	1,854		0.76%	1,542	
People with heart failure with reduced left ventricular ejection fraction	72.00%	1,335		72.00%	1,110	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms	71.10%	949		71.10%	789	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms, with a left ventricular ejection fraction of 35% or less	59.50%	565		59.50%	469	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms, with a left ventricular ejection fraction of 35% or less and taking an ACE inhibitor/ARB	85.95%	486		85.95%	403	
<b>Current practice</b>						
People having an ACE inhibitor	85.00%	413		85.00%	343	
People having an ARB	15.00%	73		15.00%	60	
People having sacubitril valsartan	0.00%	-		0.00%	-	
<b>Annual treatment costs</b>						
ACEi (weighted average)	£31.59	413	£13,046	£31.59	343	£10,835
ARB (Weighted average)	£86.71	73	£6,330	£86.71	60	£5,203
Sacubitril valsartan	£1,193.55	-	£0	£1,193.55	-	£0
<b>Estimated costs of current practice</b>			<b>£19,376</b>			<b>£16,038</b>
<b>Future practice</b>						
People having an ACE inhibitor	34.40%	167		34.40%	139	
People having an ARB	5.60%	27		5.60%	23	
People having sacubitril valsartan	60.00%	292		60.00%	242	
<b>Annual treatment costs</b>						
ACEi (weighted average)	£31.59	167	£5,275	£31.59	139	£4,391
ARB (Weighted average)	£86.71	27	£2,341	£86.71	23	£1,994
Sacubitril valsartan	£1,193.55	292	£348,517	£1,193.55	242	£288,839
<b>Estimated costs of future practice</b>			<b>£356,133</b>			<b>£295,224</b>
<b>Reduced hospital admissions associated with switching from an ACE inhibitor to sacubitril valsartan</b>						
People switching from an ACE inhibitor to sacubitril valsartan		246			204	
All-cause hospitalisation rate for heart failure associated with sacubitril valsartan	31.81%	78		31.81%	65	
Reduced annual hospital admissions using sacubitril valsartan instead of an ACE inhibitor	-3.71%	-9		-3.71%	-7	
<b>Unit costs</b>						
Heart failure	£2,697.69	-9	-£24,279	£2,697.69	-7	-£18,884
<b>Estimated costs of future practice</b>			<b>-£24,279</b>			<b>-£18,884</b>
<b>Net resource impact</b>			<b>£312,478</b>			<b>£260,303</b>
<b>Potential changes to drug costs (VAT and discounts)</b>						
VAT						
	Total VAT applicable drug costs	Drug cost including discounts and VAT	Adjustment	Total VAT applicable drug costs	Drug cost including discounts and VAT	Adjustment
Current practice	£19,376	19,376	-	£16,038	16,038	-
Future practice	356,133	356,133	-	295,224	295,224	-
<b>Impact of changes in drug cost</b>			<b>£0</b>			<b>£0</b>
<b>Amended resource impact of guidance</b>			<b>£312,478</b>			<b>£260,303</b>

**Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)**

Resource impact template	Resource impact for selected population using standard NICE assumptions			Resource impact for selected population using standard NICE assumptions		
	Northumberland			South Tees		
	Unit cost (£) / proportion	Units	Total cost (£)	Unit cost (£) / proportion	Units	Total cost (£)
Total population selected		315,806			273,884	
People with heart failure	0.76%	2,408		0.76%	2,089	
People with heart failure with reduced left ventricular ejection fraction	72.00%	1,734		72.00%	1,504	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms	71.10%	1,233		71.10%	1,069	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms, with a left ventricular ejection fraction of 35% or less	59.50%	734		59.50%	636	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms, with a left ventricular ejection fraction of 35% or less and taking an ACE inhibitor/ARB	85.95%	631		85.95%	547	
<b>Current practice</b>						
People having an ACE inhibitor	85.00%	536		85.00%	465	
People having an ARB	15.00%	95		15.00%	82	
People having sacubitril valsartan	0.00%	-		0.00%	-	
<b>Annual treatment costs</b>						
ACEi (weighted average)	£31.59	536	£16,932	£31.59	465	£14,689
ARB (Weighted average)	£86.71	95	£8,237	£86.71	82	£7,110
Sacubitril valsartan	£1,193.55	-	£0	£1,193.55	-	£0
<b>Estimated costs of current practice</b>			<b>£25,169</b>			<b>£21,799</b>
<b>Future practice</b>						
People having an ACE inhibitor	34.40%	217		34.40%	188	
People having an ARB	5.60%	35		5.60%	31	
People having sacubitril valsartan	60.00%	379		60.00%	328	
<b>Annual treatment costs</b>						
ACEi (weighted average)	£31.59	217	£6,855	£31.59	188	£5,939
ARB (Weighted average)	£86.71	35	£3,035	£86.71	31	£2,688
Sacubitril valsartan	£1,193.55	379	£452,355	£1,193.55	328	£391,484
<b>Estimated costs of future practice</b>			<b>£462,245</b>			<b>£400,111</b>
<b>Reduced hospital admissions associated with switching from an ACE inhibitor to sacubitril valsartan</b>						
People switching from an ACE inhibitor to sacubitril valsartan		319			277	
All-cause hospitalisation rate for heart failure associated with sacubitril valsartan	31.81%	101		31.81%	88	
Reduced annual hospital admissions using sacubitril valsartan instead of an ACE inhibitor	-3.71%	-12		-3.71%	-10	
<b>Unit costs</b>						
Heart failure	£2,697.69	-12	-£32,372	£2,697.69	-10	-£26,977
<b>Estimated costs of future practice</b>			<b>-£32,372</b>			<b>-£26,977</b>
<b>Net resource impact</b>			<b>£404,704</b>			<b>£351,335</b>
<b>Potential changes to drug costs (VAT and discounts)</b>						
<b>VAT</b>						
	Total VAT applicable drug costs	Drug cost including discounts and VAT	Adjustment	Total VAT applicable drug costs	Drug cost including discounts and VAT	Adjustment
Current practice	£25,169	25,169	-	£21,799	21,799	-
Future practice	462,245	462,245	-	400,111	400,111	-
<b>Impact of changes in drug cost</b>			<b>£0</b>			<b>£0</b>
<b>Amended resource impact of guidance</b>			<b>£404,704</b>			<b>£351,335</b>

**Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)**

Resource impact template	Resource impact for selected population using standard NICE assumptions			Resource impact for selected population using standard NICE assumptions		
	South Tyneside			Sunderland		
	Unit cost (£) / proportion	Units	Total cost (£)	Unit cost (£) / proportion	Units	Total cost (£)
Total population selected		148,526			276,080	
People with heart failure	0.76%	1,133		0.76%	2,105	
People with heart failure with reduced left ventricular ejection fraction	72.00%	816		72.00%	1,516	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms	71.10%	580		71.10%	1,078	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms, with a left ventricular ejection fraction of 35% or less	59.50%	345		59.50%	641	
People with heart failure with reduced ejection fraction and NYHA class II to IV symptoms, with a left ventricular ejection fraction of 35% or less and taking an ACE inhibitor/ARB	85.95%	297		85.95%	551	
<b>Current practice</b>						
People having an ACE inhibitor	85.00%	252		85.00%	468	
People having an ARB	15.00%	45		15.00%	83	
People having sacubitril valsartan	0.00%	-		0.00%	-	
<b>Annual treatment costs</b>						
ACEi (weighted average)	£31.59	252	£7,961	£31.59	468	£14,784
ARB (Weighted average)	£86.71	45	£3,902	£86.71	83	£7,197
Sacubitril valsartan	£1,193.55	-	£0	£1,193.55	-	£0
<b>Estimated costs of current practice</b>			<b>£11,863</b>			<b>£21,981</b>
<b>Future practice</b>						
People having an ACE inhibitor	34.40%	102		34.40%	190	
People having an ARB	5.60%	17		5.60%	31	
People having sacubitril valsartan	60.00%	178		60.00%	331	
<b>Annual treatment costs</b>						
ACEi (weighted average)	£31.59	102	£3,222	£31.59	190	£6,002
ARB (Weighted average)	£86.71	17	£1,474	£86.71	31	£2,688
Sacubitril valsartan	£1,193.55	178	£212,452	£1,193.55	331	£395,065
<b>Estimated costs of future practice</b>			<b>£217,148</b>			<b>£403,755</b>
<b>Reduced hospital admissions associated with switching from an ACE inhibitor to sacubitril valsartan</b>						
People switching from an ACE inhibitor to sacubitril valsartan		150			278	
All-cause hospitalisation rate for heart failure associated with sacubitril valsartan	31.81%	48		31.81%	88	
Reduced annual hospital admissions using sacubitril valsartan instead of an ACE inhibitor	-3.71%	-5		-3.71%	-11	
<b>Unit costs</b>						
Heart failure	£2,697.69	-5	-£13,488	£2,697.69	-11	-£29,675
<b>Estimated costs of future practice</b>			<b>-£13,488</b>			<b>-£29,675</b>
<b>Net resource impact</b>			<b>£191,797</b>			<b>£352,100</b>
<b>Potential changes to drug costs (VAT and discounts)</b>						
<b>VAT</b>						
	Total VAT applicable drug costs	Drug cost including discounts and VAT	Adjustment	Total VAT applicable drug costs	Drug cost including discounts and VAT	Adjustment
Current practice	£11,863	11,863	-	£21,981	21,981	-
Future practice	217,148	217,148	-	403,755	403,755	-
<b>Impact of changes in drug cost</b>			<b>£0</b>			<b>£0</b>
<b>Amended resource impact of guidance</b>			<b>£191,797</b>			<b>£352,100</b>